Skip to content

A randomized, double-blind, placebo-controlled clinical study of Shexiang Baoxin Pill in the treatment of microvascular angina pectoris (MVA) complicated with anxiety and depression

A randomized, double-blind, placebo-controlled clinical study of Shexiang Baoxin Pill in the treatment of microvascular angina pectoris (MVA) complicated with anxiety and depression

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300068549
Enrollment
Unknown
Registered
2023-02-23
Start date
2023-03-01
Completion date
Unknown
Last updated
2023-05-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Microvascular angina pectoris with anxiety and depression

Interventions

control group:Shexiang Baoxin Pill Simulant+Western medicine treatment
Test group:Shexiang Baoxin Pill+western medicine treatment

Sponsors

Xiyuan Hospital, Chinese Academy of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) It meets the diagnostic criteria of microvascular angina pectoris in western medicine; (2) Meet the diagnostic criteria for anxiety, 5 points = GAD-7 score = 14 points; (3) Meet the diagnostic criteria for depression, 5 points = PHQ-9 score = 14 points; (4) Conforming to the above diagnostic criteria of Qi stagnation and blood stasis syndrome; (5) Age: 20-75 years old, male or female; (6) Subjects were informed and voluntarily signed the informed consent form. Compliance with (1), (2) or (3) and (4)~(6) can be included

Exclusion criteria

Exclusion criteria: (1) Have obvious liver and kidney diseases, or ALT and AST are 1.5 times higher than the upper limit of normal, and Cr and BUN are higher than the upper limit of normal; (2) Patients with severe heart failure, myocardial disease, structural heart disease, uncontrolled hypertension and other serious cardiovascular diseases; (3) Patients with serious mental illness, hematopoietic system disease, malignant tumor and other major diseases; (4) Patients who have taken anti-anxiety and depression drugs for a long time or within a week; (5) Have serious suicidal tendencies; (6) Pregnant or pregnant women, lactating women; (7) Those who have participated or are participating in other clinical research in the past three months; (8) Suspicious or definite allergy to the study drug.

Design outcomes

Primary

MeasureTime frame
Seattle Angina Scale;

Secondary

MeasureTime frame
TCM syndrome score;Generalized anxiety scale;Inflammatory factor;Anti-inflammatory factor;Vascular endothelial injury markers;Peripheral blood neurotransmitter;

Countries

China

Contacts

Public ContactLong linzi

Xiyuan Hospital, Chinese Academy of Traditional Chinese Medicine

qixiang830803@163.com+86 15801152337

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026